Elicio Therapeutics Reports $11.8 Million Net Loss in Q1 2026

Elicio Therapeutics, Inc. reported a net loss of $11.8 million for the first quarter of 2026, a slight increase from the $11.2 million loss recorded in the same period of 2025. The company's total operating expenses for the quarter were $10.6 million, a marginal decrease of 1% compared to $10.7 million in the prior year. Research and development expenses decreased by 13% to $6.8 million, primarily due to reduced clinical trial costs as the Phase 2 study of ELI-002 7P transitioned from the active dosing phase to follow-up. Conversely, general and administrative expenses rose by 30% to $3.8 million, attributed to increased personnel costs and professional fees.

As of March 31, 2026, Elicio's cash and cash equivalents stood at $14.9 million, down from $18.6 million at the end of 2025. The company has an accumulated deficit of $245.5 million, raising concerns about its ability to continue as a going concern. Elicio anticipates that its current cash position will fund operations into the fourth quarter of 2026, contingent on its financial operating plan. The company plans to address its liquidity needs through potential equity offerings, debt financing, or strategic partnerships, although it acknowledges the uncertainty surrounding the availability of such financing.

In terms of operational developments, Elicio is advancing its lead product candidate, ELI-002 7P, which is currently in a Phase 2 clinical trial targeting mKRAS-positive pancreatic cancer. The Independent Data Monitoring Committee has recommended that the trial continue without modifications, confirming a favorable safety profile. The final analysis of disease-free survival is expected mid-year 2026. Additionally, Elicio has initiated a new At Market Issuance Sales Agreement under a 2026 Registration Statement, allowing for the issuance of up to $100 million in common stock, with $1.3 million raised in the first quarter of 2026.

The company’s total assets decreased to $22.7 million from $25.9 million at the end of 2025, primarily due to the reduction in cash and cash equivalents. Elicio's liabilities remained relatively stable, totaling $24.1 million as of March 31, 2026. The company continues to rely on third-party collaborations for clinical trials and manufacturing, which are critical for advancing its product candidates. Elicio's management remains focused on expanding its pipeline and achieving regulatory approvals, while also managing its financial resources carefully to navigate the challenges ahead.